Neoadjuvant nivolumab plus chemotherapy increases event-free survival in resectable non-small-cell lung cancer
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read MoreApr 18, 2022
1. Neoadjuvant nivolumab plus chemotherapy led to a longer event-free survival and higher...
Read MoreApr 12, 2022
1. Patients in the control group had higher mean health care utilization costs across the...
Read MoreApr 12, 2022
1. In this retrospective cohort study, 462 patients with locally advanced gastric cancer...
Read MoreApr 8, 2022
For a study, researchers sought to explore the hypothesis that neonatal hypoglycemia is related to...
Read MoreApr 7, 2022
For a study, researchers sought to investigate the effects of preventive dextrose gel on...
Read MoreApr 7, 2022
For a study, researchers sought to look at the relationship between (Left Atrial) LA function and...
Read MoreApr 5, 2022
Click to read this study in JAMA Oncology.
Read MoreApr 5, 2022
1. Carotuximab in tandem with pazopanib did not show improvement in progression-free survival or...
Read MoreApr 5, 2022
1. Adherence to the guidelines increased from 38% to 56% between Fall 2016 and 2019; and from 37%...
Read MoreApr 5, 2022
1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and...
Read MoreApr 2, 2022
1. In this study, patients who were obese or overweight had better survival compared to normal...
Read MoreMar 29, 2022
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of...
Read MoreMar 29, 2022
1. Overall survival was significantly longer in patients taking darolutamide in tandem with...
Read MoreMar 29, 2022
1. Longer progression-free survival was found in patients taking trastuzumab deruxtecan compared...
Read MoreMar 29, 2022
1. Patients with hormone-sensitive prostate cancer receiving darolutamide, an androgen-receptor...
Read MoreMar 25, 2022
1. This study found there was a positive association between religious attendance and cancer...
Read MoreMar 25, 2022
“Older adults with cancer are underrepresented in clinical trials, despite comprising the majority...
Read MoreMar 21, 2022
1. Treatment with pembrolizumab yielded a best overall response rate of 71%. 2. Adverse events...
Read MoreMar 21, 2022
1. Overall survival was longer in the group receiving ribociclib with letrozole as compared with...
Read MoreMar 21, 2022
1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in...
Read More